ASCO-GI 2023: Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC).
ArtStation - LS 2070 - SECURITY BOT
Build bots on Zoho for your workplace | How to make bots - Zoho Cliq
Project Destroyer (@destroyerbots) / Twitter
Bot MD Care - Peritonitis Detection - YouTube
Discord Bots
PagerDuty OnCall Slack bot | Devpost
Projet Destroyer (PD) Bot Review. Is PD For Sale and For What Price?